This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jani, J. P. Articles by Bhattacharya, S. K. Search for Related Content PubMed PubMed Citation Articles by Jani, J. P. Articles by Bhattacharya, S. K.

Discovery and Pharmacologic Characterization of CP-724,714, a Selective ErbB2 Tyrosine Kinase Inhibitor

¹ Department of Cancer Discovery, Pfizer Global Research and Development, Groton, Connecticut and ² Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California

Requests for reprints: Samit K. Bhattacharya, Department of Cancer Discovery, Pfizer Global Research and Development, Groton, CT 06340. Phone: 860-715-4028; Fax: 860-686-5640; E-mail: samit.k.bhattacharya{at}pfizer.com.

Amplification and overexpression of erbB2 (Her-2/neu) proto-oncogene has been linked to human malignancies including tumors of the breast, ovary, and stomach. It has been implicated in tumor growth, sensitivity to standard chemotherapy, prognosis of patients, and disease-free survival. Although the clinical use of trastuzumab (Herceptin) has prolonged the survival of breast cancer patients with erbB2-overexpressing tumors, there is an urgent need for more potent and orally bioavailable small-molecule inhibitors. CP-724,714 is a potent inhibitor of erbB2 receptor autophosphorylation in intact cells and is currently undergoing phase I clinical trials. Here, we describe the effects of CP-724,714 in vitro and in vivo in human breast cancer models. CP-724,714 is selective for inhibiting growth of HER2-driven cell lines. In addition, we show that it induces G₁ cell cycle block in erbB2-overexpressing BT-474 human breast carcinoma cells and inhibits erbB2 autophosphorylation in xenografts when administered p.o. to athymic mice. It induces a marked reduction of extracellular signal–regulated kinase and Akt phosphorylation, tumor cell apoptosis, and release of caspase-3. P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects. [Cancer Res 2007;67(20):9887–93]

This article has been cited by other articles:

				X. Liu, M. Abdelrahim, A. Abudayyeh, P. Lei, and S. Safe The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression Mol. Cancer Ther., May 1, 2009; 8(5): 1207 - 1217. [Abstract] [Full Text] [PDF]

				B. Feng, J. J. Xu, Y.-A. Bi, R. Mireles, R. Davidson, D. B. Duignan, S. Campbell, V. E. Kostrubsky, M. C. Dunn, A. R. Smith, et al. Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714 Toxicol. Sci., April 1, 2009; 108(2): 492 - 500. [Abstract] [Full Text] [PDF]

				N. E Hynes ErbB Receptors in Cancer: HER2/ErbB2 as a Therapeutic Target Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 123 - 130. [Abstract] [Full Text] [PDF]